Aurobindo Pharma ties up with BIRAC to develop Covid-19 vaccine

A well-integrated pharma company, Aurobindo Pharma features among the top 2 Pharmaceutical companies in India in terms of consolidated revenues. Aurobindo exports to over 150 countries across the globe with around 90 per cent of revenues derived from international operations.  

The Council of Scientific and Industrial Research (CSIR) and Aurobindo Pharma on Tuesday announced a collaboration to develop vaccines for COVID-19.

As per the release issued by the Centre for Cellular & Molecular Biology (CCMB), under the signed agreement between CSIR- CCMB and Aurobindo Pharma, Aurobindo will partner with CSIR for the development of several novel COVID-19 vaccines.

Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax and Biological E are among the pharma firms in India working on the coronavirus vaccine.

At 2:50 pm on Wednesday, the share of Aurobindo Pharma was trading at Rs 830 with gains of 1.48 per cent with an intraday high of Rs 850.80.